Hemodynamic effects of MF 10058, a new cardioselective muscarinic M2 receptor antagonist, in conscious dogs

European Journal of Pharmacology

Volumn 406, Issue 1, 2000, Pages 93-98

  Lamperti, Giuseppina ^a   Champeroux, Pascal ^b   Martel, Eric ^b   Colibretti, Maria Luisa ^a   Santoro, Luigi ^a   Imbimbo, Bruno P ^a  

^a Research and Development Department   (Italy)

^b Centre de Recherches Biologiques   (France)

Author keywords

Antibradycardic agent; Bradycardia; Cardioselective muscarinic receptor antagonist; MF 10058; Muscarinic M2 receptor antagonist; Sick sinus syndrome

Indexed keywords

MF 10058; MUSCARINIC M2 RECEPTOR; MUSCARINIC M2 RECEPTOR ANTAGONIST; MUSCARINIC RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRADYCARDIA; CARDIOSELECTIVITY; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOG; FEMALE; HEART HEMODYNAMICS; MALE; NONHUMAN; PRIORITY JOURNAL; QT INTERVAL; SICK SINUS SYNDROME;

ANIMALS; AZEPINES; BLOOD PRESSURE; CIRCADIAN RHYTHM; CONSCIOUSNESS; DIASTOLE; DOGS; FEMALE; HEART RATE; HEMODYNAMIC PROCESSES; MALE; MUSCARINIC ANTAGONISTS; PIPERIDINES; RECEPTOR, MUSCARINIC M2; RECEPTORS, MUSCARINIC; SYSTOLE; TIME FACTORS;

EID: 0034613232     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(00)00611-7     Document Type: Article

References (37)

1. Akselrod S., Gordon F., Ubel F.A., Shannon D.C., Barger A.C., Cohen R.J. Power spectrum analysis of heart rate fluctuation: a quantitative probe of beat-to-beat cardiovascular control. Science. 213:1981;220-223.
2. Anderson D.E., Talan M.I., Engel B.T. Nocturnal hemodynamic patterns in dogs. Physiol. Behav. 48:1990;485-487.
3. Berlad I., Shlitner A., Ben-Haim S., Lavie P. Power spectral analysis and heart rate variability in stage 4 and REM sleep: evidence for state-specific changes in autonomic dominance. J. Sleep Res. 2:1993;88-90.
4. Bootsma M., Swenne C.A., Van Bolhuis H.H., Chang P.C., Cats V.M., Bruschke A.V.G. Heart rate and heart rate variability as indexes of sympathovagal balance. Am. J. Physiol. 266:1994;H1565-H1571.
5. Caulfield M.P. Muscarinic receptors-characterization, coupling and function. Pharmacol. Ther. 58:1993;319-379.
6. Deighton N.M., Motomura S., Borguez D., Zerkowski H.R., Doetsch N., Brodde O.E. Muscarinic cholinoceptors in human heart: demonstration, subclassification and distribution. Naunyn-Schmiedeberg's Arch. Pharmacol. 341:1990;14-21.
7. DeJonge A., Dämmgen J., Doods H.N. Muscarinic receptors in the cardiovascular system. Prog. Pharmacol. 6:1986;133-153.
8. DiFrancesco D., Ducouret P., Robinson R.B. Muscarinic modulation of cardiac rate at low acetylcholine concentration. Science. 243:1989;669-671.
9. Eglen R.M., Whiting R.L. Heterogeneity of vascular muscarinic receptors. J. Auton. Pharmacol. 19:1990;233-245.
10. Gadsby D.C, Wit A.L, Cranefield P.F. The effects of acetylcholine on the electrical activity of canine cardiac Purkinje fibers. Circ. Res. 43:1978;29-35.
11. 2 receptor antagonist. Life Sci. 38:1986;1663-1672.
12. Goyal R.K. Muscarinic receptor subtypes. Physiology and clinical implications. N. Engl. J. Med. 321:1989;1022-1029.
13. Hashimoto M., Kuwahara M., Tsubone H., Sugano S. Diurnal variation of autonomic nervous activity in the rat: investigation by power spectral analysis of heart rate variability. J. Electrocardiol. 32(2):1999;167-171.
14. Hendrix P.K., Robinson E.P., Raffe M.R. Methoctramine, a cardioselective muscarinic cholinergic antagonist, prevents fentanyl-induced bradycardia in the dog. J. Vet. Pharmacol. Ther. 18:1995;87-93.
15. Hlucky J., Milovsky V., Pavlovic M., Uhliarikova H., Makovini M. Parasympathetic overactivity and its evaluation in patients with sinus nodal dysfunction. Int. J. Cardiol. 33:1991;357-364.
16. Hulme E.C., Birdsall N.J.M., Buckley N.J. Muscarinic receptor subtypes. Annu. Rev. Pharmacol. Toxicol. 30:1990;633-677.
17. Jeck D., Lindmar R., Löffelholz K., Wanke M. Subtypes of muscarinic receptors on cholinergic nerves and atrial cells of chicken and guinea-pig hearts. Br. J. Pharmacol. 93:1988;357-366.
18. Kalsner S. Cholinergic constriction in the general circulation and its role in coronary artery spasm. Circ. Res. 65:1989;237-257.
19. Kuwahara M., Suzuki A., Tsutsumi H., Tanigawa M., Tsubone H., Sugano S. Power spectral analysis of heart rate variability for assessment of diurnal variation of autonomic nervous activity in miniature swine. Lab. Anim. Sci. 49:1999;202-208.
20. Levey A.I. Immunological localization of m1-m5 muscarinic acetylcholine receptors in peripheral tissues and brain. Life Sci. 52:1993;441-448.
21. Levy M.N., Warner M.R. Parasympathetic effects on cardiac function. Armour J.A, Ardell J.L. Neurocardiology. 1994;53-76 Oxford Univ. Press, New York.
22. Lüscher T.F., Boulanger C.M., Dohi Y., Yang Z. Endothelium-derived contracting factors. Hypertension. 19:1992;117-130.
23. Malliani A., Lombardi F., Pagani M. Power spectrum analysis of heart rate variability: a tool to explore neural regulatory mechanisms. Br. Heart J. 71:1994;1-2.
24. 2 muscarinic antagonists. Chem. Pharm. Bull. 2000;. in press.
25. Micheletti R., Montagna E., Giachetti A. AF-DX 116, a cardioselective muscarinic antagonist. J. Pharmacol. Exp. Ther. 241:1986;628-634.
26. Mutschler E., Moser U., Wess J., Lambrecht L. Muscarinic subtypes: agonists and antagonists. Prog. Pharmacol. 7:1989;13-31.
27. Nakagawa M., Iwao T., Yonemochi H., Fujino T., Saikawa T., Ito M. Circadian rhythm of the signal averaged electrocardiogram and its relation to heart rate variability in healthy subjects. Heart. 79:1998;493-496.
28. 1 receptor subtype on chronotropic and dromotropic responses to vagus stimulation in anesthetized dogs. J. Pharmacol. Exp. Ther. 258:1991;166-170.
29. Otzenberger H., Gronfier C., Simon C., Charloux A., Ehrhart J., Piquard F., Brandenberger G. Dynamic heart rate variability: a tool for exploring sympathovagal balance continuously during sleep in men. Am. J. Physiol. 275:1998;H946-H950.
30. Pomeranz B., Macaulay R.J.B., Caudill M.A., Kutz I., Adam D., Gordon D., Kilborn K.M., Barger A.C., Shannon D.C., Cohen R.J., Benson H. Assessment of autonomic function in human by heart rate spectral analysis. Am. J. Physiol. 248:1985;H151-H153.
31. Santinelli V., Chiariello M., Clarizia M., Condorelli M. Sick sinus syndrome: the role of hypervagotonia. Int. J. Cardiol. 5:1984;532-535.
32. Stein K.M., Lippman N., Lerman B.B. Heart rate variability and cardiovascular risk assessment. Laragh J.H., Brenner B.M Hypertension: Pathophysiology, Diagnosis and Management. 1995;889-903 Raven Press, New York.
33. Tan H.L., Hou C.J.Y., Lauer M.R., Sung R.J Electrophysiologic mechanism of the long QT interval syndromes and torsade de pointes. Ann. Intern. Med. 122:1995;701-714.
34. Toscani L., Gangemi P.F., Parigi A., Silipo R., Ragghianti A., Sirabella E., Morelli M., Bagnoli L., Vergassola R., Zaccara G. Human heart rate variability and sleep stages. Ital. J. Neurol. Sci. 17:1996;437-439.
35. Tse W.W., Han J., Yoon M.S. Effect of acetylcholine on automaticity of canine Purkinje fibers. Am. J. Physiol. 230:1976;116-119.
36. Vanoli E., Adamson P.B., Ba-Lin M.S., Pinna G.D., Lazzara R., Orr W.C. Heart rate variability during specific sleep stages. A comparison of healthy subjects with patients after myocardial infarction. Circulation. 91:1995;1918-1922.
37. 2 muscarinic receptor antagonists. Chem. Pharm. Bull. 46:1998;53-68.